Skip to main content

Table 3 Operative parameters

From: Combining aortic arch dissection stent implantation and root surgery for aortic dissection type A

 

AMDS

Control

P-value

(n = 9)

(n = 111)

EuroScore II, % (mean ± SD)

15.7 ± 3.7

25.4 ± 15.3

0.09

Duration

 Overall, min (mean ± SD)

471 ± 83

382 ± 103

0.09

 Cardiopulmonary bypass, min (mean ± SD)

313 ± 53

248 ± 76

< 0.01

 Aortic cross clamp, min (mean ± SD)

201 ± 50

149 ± 48

< 0.01

 Circulatory arrest, min (mean ± SD)

52 ± 12

30 ± 15

< 0.01

 Bilateral antegrade cerebral perfusion, min (mean ± SD)

38 ± 15

33 ± 45

0.03

 Reperfusion, min (mean ± SD)

88 ± 22

78 ± 38

0.13

Operative procedures

 Replacement of ascending aorta, n (%)

9 (100.0)

111 (100.0)

> 0.99

 Valve-sparing root replacement, n (%)

5 (55.6)

54 (48.6)

0.74

 Aortic valve replacement

  Bioprosthesis, n (%)

4 (44.4)

54 (48.6)

> 0.99

  Mechanical prosthesis, n (%)

0 (0.0)

3 (2.7)

> 0.99

 Coronary artery bypass graft, n (%)

0 (0.0)

37 (33.3)

0.06

Arterial cannulation for cardiopulmonary bypass

 Right subclavian artery, n (%)

7 (77.8)

72 (64.9)

0.72

 Ascending aorta, n (%)

2 (22.2)

22 (19.8)

> 0.99

 Femoral artery, n (%)

0 (0.0)

19 (17.1)

0.35

 Apex, n (%)

0 (0.0)

1 (0.9)

> 0.99

Antegrade perfusion

 Right subclavian artery, n (%)

9 (100.0)

102/106 (96.2)

> 0.99

 Left common carotid artery, n (%)

9 (100.0)

101/106 (95.3)

> 0.99

 Left subclavian artery, n (%)

1 (11.1)

19/106 (17.9)

> 0.99

Minimal body core temperature, °C (mean ± SD)

26.5 ± 0.8

26.6 ± 4.2

0.74

Intraoperative peak lactate, mmol/l (mean ± SD)

9.06 ± 4.00

7.93 ± 4.45

0.18

Aortic rupture, n (%)

1 (11.1)

6 (5.4)

0.43

Blood transfusion, n (%)

9 (100.0)

111 (100.0)

> 0.99

 Packed red blood cells, n (mean ± SD)

9.8 ± 8.7

9.9 ± 6.1

0.49

 Packed platelets, n (mean ± SD)

5.6 ± 2.5

4.9 ± 2.4

0.51

Intraoperative death, n (%)

0 (0.0)

1 (0.9)

> 0.99

  1. Operative procedures for acute type A aortic dissection. Patients with additional implantation of a novel non-covered hybrid prosthesis (AMDS, ARTIVION, Kennesaw, USA) (AMDS, n = 9) were compared to controls (n = 111)